# Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Maud Toulmonde, Sophie Cousin, Michele Kind, Jean-Philippe Guegan, Alban Bessede, Francois Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera, Antoine Italiano

► To cite this version:

Maud Toulmonde, Sophie Cousin, Michele Kind, Jean-Philippe Guegan, Alban Bessede, et al. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. Journal of Hematology and Oncology, 2022, 15 (1), pp.149. 10.1186/s13045-022-01370-9. hal-04008638

HAL Id: hal-04008638

https://hal.science/hal-04008638

Submitted on 28 Feb 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
**CORRESPONDENCE**

Open Access

<figure><img src="image_2.png" /></figure>

Check for
updates

# Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Maud Toulmonde<fnref n="1" />, Sophie Cousin<fnref n="1" />, Michèle Kind², Jean-Philippe Guegan³, Alban Bessede³, Francois Le Loarer⁴,⁵, Raul Perret⁴, Coralie Cantarel⁶,⁷, Carine Bellera⁶,⁷ and Antoine Italiano<fnref n="1" />,⁵*

**Abstract**

JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of the METROMAJX which is a randomized phase II clinical trial investigating the combination of JX-594 combined with metronomic cyclophosphamide (arm 1) or metronomic cyclophosphamide (arm 2) in patients with advanced STS. A two-stage Simon design was used. JX-594 was administered intra-venously at the dose 1.109 every 2 weeks for the first 3 injections and then every 3 weeks. Cyclophosphamide was given orally at the dose of 50 mg BID 1 week on 1 week off. The primary endpoint was the 6-month non progression rate. 20 patients were included (arm 1:15, arm 2:5). The two most frequent toxicities were grade 1 fatigue and fever and grade 2 fatigue and grade 2 lymphopenia in arms 1 and 2, respectively. In arm 1, 12 patients were assessable for the efficacy analysis. None of them were progression-free at 6 months indicating that the first stage of the Simon's design was not satisfied. One patient out 4 assessable for efficacy was progression-free at 6 months in arm 2. High throughput analysis of sequential plasma samples revealed an upregulation of protein biomarkers reflecting immune induction such as CXCL10 and soluble CD8 antigen in arm 1. Systemic treatment with JX-594 is safe in patients with advanced STS. Further investigations are needed to improve immune response to oncolytic viruses and define their therapeutic potential in patients with STS.

**Keywords:** Soft-tissue sarcoma, Virus oncolytics, JX-594, Low-dose cyclophosphamide

**To the Editor,**

Treatment of patients with advanced/metastatic soft-tissue sarcomas (STS) is dominated by conventional chemotherapy regimens with limited clinical activity. Therefore, there is an unmet need for combinations that would improve survival with limited toxicity.

Metronomic chemotherapy (MC) is defined as frequent and regular administration of low dose of a cytotoxic agent [1]. MC combines both antiangiogenic and immunomodulatory properties that make it a 'niche' multi-targeted therapy. STS represent one of the most frequent indications for routine use of metronomic cyclophosphamide in adult with solid tumors, with some clinical activity reported in prospective and retrospective studies [2].

JX-594 (Pexa-Vec; Jennerex Inc.) is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus (OV) expressing granulocyte–macrophage colony stimulating factor (GM-CSF). It selectively destroys cancer cells

<footnote>*Correspondence: a.italiano@bordeaux.unicancer.fr</footnote>

<footnote n="1">¹ Early Phase Trials and Sarcoma Units, Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux, France
Full list of author information is available at the end of the article</footnote>
through replication-dependent cell lysis and stimulation of antitumoral immunity. JX-954 also infects tumor-associated endothelial cells in a dose-dependent manner and induces vascular disruption. JX-594 has demonstrated a favorable safety profile and activity in preclinical and early clinical studies, both after intra-tumoral (IT), single and repeated intravenous (IV) injections at dose up to $3 \times 10^9$ pfu/dose [3, 4].

TK gene expression is controlled by cellular E2F activity. Because of its selectivity for cells with up-regulation of TK gene expression, JX-594 could have a preferred activity in tumor cells with deregulation of pRB/E2F pathway, a deregulation that is frequent in STS [5].

Interestingly, metronomic cyclophosphamide has showed a synergistic effect on immuno-stimulation and promising clinical activity when combined with oncolytic adenovirus [6].

We therefore hypothesized that the association of metronomic cyclophosphamide and JX-594 could have a synergistic antitumor, and immuno-stimulating activity in patients with advanced STS.

Between April 2017 and February 2018, 20 patients with advanced STS were enrolled in the METROMAJX study, which is a randomized phase 2 trial (see Additional file 1 for further details). Eligible patients were randomly assigned (2:1) to receive either low dose cyclophosphamide (50 mg BID 1 week on 1 week off) or a regimen combining low dose cyclophosphamide 50 mg BID 1 week on, and JX-594 at the dose 1.109 every 2 weeks for the first 3 injections and then every 3 weeks. Fifteen patients were randomized in the low dose cyclophosphamide and JX-594 combination arm (arm 1) and 5 in the low-dose cyclophosphamide arm (arm 2). Three patients were excluded from the efficacy analysis in arm 1 since they did not receive one complete cycle of treatment (Fig. 1). One patient was excluded from the efficacy analysis in arm 2 since the original diagnosis was not soft-tissue sarcoma but bone Ewing sarcoma (Fig. 1). Baseline patient characteristics are listed in Additional file 1: Table S1. Patients were heavily pre-treated: 10 patients (50% of the enrolled population) had received more than two previous lines, with a median number of previous lines of three (min:0–max:8) (Additional file 1: Table S1).

After a median follow-up of 31.5 months (95% CI 20.9–34.7, reverse Kaplan–Meier), all the patients discontinued treatment. In arm 1, discontinuation was related to disease progression in 14 cases and to patient's decision in one case. In arm 2, discontinuation was related to disease progression in 4 cases and to patient's decision in one case. In arm 1, 12 patients were assessable for the efficacy analysis (Additional file 1: Fig. S1). None of them were progression-free at 6 months indicating the

first stage of the Simon's design was not satisfied. Best response as per RECIST criteria was stable disease for 3 patients and progressive disease for 9 patients (Fig. 1A–D). In arm 2, 4 patients were eligible for the efficacy analysis. Best response was stable disease for all of them (Fig. 1A–D).

8 patients died during the study, all of them were randomized in arm 1. Death was due to disease progression in all the cases. In arm 1, median progression-free survival and overall survival were 1.7 months (95% CI 1.1–5.5) and 14.2 months (95% CI 4.1–36.4) respectively (Fig. 1C, D). In arm 2, median progression-free survival was 7.0 months (95% CI 3.6–9.6) and not reached for overall survival respectively (Fig. 1E, F).

All the patients were included in the safety analysis. At the time of analysis, 47 cycles of JX-594 and metronomic CP had been administered, with a median of 2 cycles per patient (range 1–8) in arm 1. The most observed toxicities were grade 1 fever and grade 1 fatigue (Additional file 1: Table S2). Grade 3 toxicities were rare (observed in 2 patients) and included two cases of grade 3 fever and one case of grade 3 lymphopenia. No grade 4 toxicity was observed.

In arm 2, 43 cycles of metronomic CP were administered with a median of 10 cycles per patient (range 2–15). Grade 2 fatigue and grade 2 lymphopenia were the most frequent event adverse events (Additional file 1: Table S3). One patient experienced a grade 3 adverse event (anemia).

To evaluate the immune response to oncolytic virotherapy, we performed a proteomic analysis of plasma samples (see Additional file 1). Although only few changes in plasma proteome were observed between C1D8 and baseline (first administration of low dose cyclophosphamide), comparison of plasma samples between C1D22 and C1D8 (first injection of JX-594) revealed a significant upregulation of several proteins which reflect immune induction such as CD8A, and lymphocyte trafficking chemokines such as Cxcl10 but also of immunosuppressive cytokines such as IL-18 and TGFbeta (Additional file 1: Fig. S2).

We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication administered systemically in patients with STS. Although we observed low clinical activity, the results of our study pave the way for innovative approach to be evaluated in patients with advanced STS.

By analyzing transcriptomic data from >600 soft-tissue sarcomas (STSs), we found that up to 60% of STS are poorly infiltrated by immune cells and have low expression of PD-L1 on their surface [7]. By activating an immune response to the tumor cells due to viral infection, OVs have the potential to turn the “cold” tumor
<figure><img src="image_3.png" /></figure>

microenvironment to “hot” and to sensitize tumors to immune checkpoint inhibitors as recently demonstrated in a pre-clinical model of triple negative breast cancer [8]. Interestingly, by using plasma proteomics, we have found that JX-594 treatment was associated with

an upregulation of cytokines involved in anti-tumor immune response such as CXCL10, a chemokine playing a crucial role in recruiting activated T cells into sites of tissue inflammation and with the presence of CD8+ [9]. Interestingly, we found an increase in soluble CD8
antigen (CD8A) which is released in response to lymphocyte activation. Overall, these findings agree with those of a recent study investigating the immunomodulatory effect of JX-594 given before surgical resection of metastases in patients with colorectal cancer and melanoma. However, we also found an upregulation of immunosuppressive cytokines such as TGFb and IL18 revealing the potential complexity of the immunomodulatory effects of JX-594 and their impact of tumor microenvironment.

A recent study has reported the results of a single-center, phase II which investigated the combination of talimogene laherparepvec (T-VEC), an oncolytic immunotherapy derived from a modified human herpes simplex virus type 1, with pembrolizumab in patients with advanced STS [10]. T-VEC was administered intratumorally. 20 patients were enrolled in the trial. Most of them had locally advanced disease. Objective responses were observed in 30% of patients across 5 different histological subtypes. Given these promising results, whether the combination of JX-594 with an immune checkpoint inhibitor could be associated with meaningful clinical activity is therefore worth to investigate. A clinical trial assessing the combination of intra-tumoral JX-594 with the PD-L1 antagonist avelumab in patients with STS is ongoing (NCT02630368).

Although the number of patients enrolled in arm 2 was limited, due to fact that the accrual stopped at the end of the first stage, our data confirmed the results from retrospective studies suggesting that metronomic chemotherapy may have some clinical activity in patients with advanced sarcoma [2]. Indeed, all the patients enrolled in our study had disease progression confirmed at inclusion based on central review of two imaging performed at less than a 6-month interval. Interestingly, all of them had stable disease as best response and one of them was progression free at 6 months. Our study is the first one assessing prospectively the efficacy of metronomic cyclophosphamide in patients with advanced STS. Based on these preliminary results, a phase 3 study is currently comparing the efficacy of doxorubicin versus metronomic cyclophosphamide in patients aged more than 65 years old with metastatic STS (NCT04757337).

In conclusion, our study confirms that systemic administration of a genetically modified oncolytic virus is safe in patients with advanced STS. The role of the combination with other immune-oncology agents such as immune checkpoint inhibitors and the identification of the population of patients who are more likely to benefit from this approach are questions of major interest.

**Abbreviations**

CP: Circulating tumor cell; PFS: Progression-free survival; STS: Soft-tissue sarcoma; TK: Thymidine kinase; OS: Overall survival.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13045-022-01370-9.

Additional file 1. Supplementary methods.

**Acknowledgements**

None.

**Author contributions**

MT and AI contributed to concept and design; all authors contributed to acquisition, analysis, or interpretation of data; AI performed drafting of the manuscript and supervision; all authors made critical revision of the manuscript for important intellectual content; CC and CB carried out statistical analysis; AI provided administrative, technical, or material support; all authors performed validation. All authors read and approved the final manuscript.

**Funding**

This research did receive funding from Institut National du Cancer and from the Association pour la Recherche contre le Cancer.

**Availability of data and materials**

The datasets generated during and/or analyzed during the current study are not publicly available due to the clinical and confidential nature of the material but can be made available from the corresponding author on reasonable request.

**Declarations**

**Ethics in approval and consent to participate**

This study was approved by the Comité de Protection des Personnes (CPP) Sud-Ouest et Outre Mer III (Bordeaux, France) according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.

**Consent for publication**

The article does not contain any individual person's data.

**Competing interests**

AI: Research grant (AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar). The other authors declare that they have no competing interests.

**Author details**

¹Early Phase Trials and Sarcoma Units, Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux, France. ²Department of Medical Imaging, Institut Bergonié, Bordeaux, France. ³Explicyte, Bordeaux, France. ⁴Department of Pathology, Institut Bergonié, Bordeaux, France. ⁵Faculty of Medicine, University of Bordeaux, Bordeaux, France. ⁶Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Univ. Bordeaux, 33000 Bordeaux, France. ⁷Inserm CIC1401, Clinical and Epidemiological Research Unit, Comprehensive Cancer Center, Institut Bergonié, 33000 Bordeaux, France.

Received: 28 July 2022 Accepted: 5 September 2022

Published online: 21 October 2022

**References**

1. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455-65.

2. Mir O, Domont J, Cioffi A, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011;47:515-9.

3. Breitbach C J, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99-102.
4. Lee J, Park YS, Burke J, et al. Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immuno-therapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC). J Clin Oncol. 2013;31:3608.

5. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer. 1995;72:986-91.

6. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011;19:1737-46.

7. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautès-Fridman C, Tawbi HA, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556-60.

8. Niavarani SR, Lawson C, Boudaud M, Simard C, Tai LH. Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality. J Immunother Cancer. 2020;8(1):e000465.

9. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168(7):3195-204.

10. Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020;6(3):402-8.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_4.png" /></figure>